The estimated percentage of activities completed by the company as per agreement.

No definition available.

Name:	limn_EstimatedPercentageOfActivitiesCompleted
Namespace Prefix:	limn_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Value of membership interest exchange for license fees being offset to additional paid-in capital.

+ References

No definition available.

+ Details

Name:	limn_LicenseRightsValueOfUnitsOffsetFromAdditionalPaidInCapital
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of member units exchanged as a consideration for license rights to develop, market and sell YN1203, InnoBation Bio CAR NK biomarkers, including devices, compounds and products used to detect analyte in body or tissue.

+ References

No definition available.

+ Details

Name:	limn_NumberOfUnitsExchangeForLicenseRights
Namespace Prefix:	limn_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of payment made for costs associated with clinical trials.

+ References

No definition available.

+ Details

Name:	limn_PaymentForCostsAssociatedWithClinicalTrials
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of prepaid research and development classified as current.

+ References

No definition available.

+ Details

Name:	limn_PrepaidResearchAndDevelopmentExpenseCurrent
Namespace Prefix:	limn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=limn_Cd47LicenseAndDevelopmentAgreementWithInnobationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=limn_CurisBiotechHoldingsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=limn_InnobationBioCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - CD47 License (Details) - USD ($)		3 Months Ended		12 Months Ended
License Agreements - CD47 License (Details) - USD ($)	Feb. 20, 2026	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2024	Dec. 31, 2025	Oct. 31, 2022
License Agreements
Research and development expense related to the CD47 License		$ 400,000		$ 2,685,334
CD47 License agreement with InnoBation
License Agreements
Percentage of activities completed		40.00%
Prepaid research and development costs		$ 600,000			$ 0
Research and development expense related to the CD47 License		$ 400,000	$ 0
CD47 License agreement with InnoBation \| Curis Biotech Holdings LLC \| Class A Member Units
License Agreements
Number of member units exchange for license rights to develop						78,555,554
Value of membership interest offset to additional paid-in capital						$ 800,000
CD47 License agreement with InnoBation \| Innobation Bio Co. Ltd
License Agreements
Company issued a payment	$ 1,000,000